Filing Details

Accession Number:
0001209191-21-013184
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-23 16:19:02
Reporting Period:
2021-02-18
Accepted Time:
2021-02-23 16:19:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
831547 Spectrum Pharmaceuticals Inc SPPI Pharmaceutical Preparations (2834) 930979187
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1726378 J Thomas Riga 11500 S. Eastern Ave., Suite 240
Henderson NV 89052
Evp, Coo & Cco No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.001 Par Value Acquisiton 2021-02-18 134,410 $0.00 464,668 No 4 A Direct
Common Stock, $0.001 Par Value Disposition 2021-02-19 5,018 $3.64 459,650 No 4 S Direct
Common Stock, $0.001 Par Value Disposition 2021-02-22 5,000 $3.73 454,650 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2021-02-18 162,921 $0.00 162,921 $3.56
Common Stock Stock Appreciation Right Acquisiton 2021-02-18 382,865 $0.00 382,865 $3.56
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
162,921 2031-02-18 No 4 A Direct
382,865 2031-02-18 No 4 A Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, $0.001 Par Value 14,139 Indirect By 401(k) plan
Footnotes
  1. One third of the aggregate amount of restricted shares shall vest on each of February 18, 2022, 2023 and 2024, respectively.
  2. All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer.
  3. One third of the aggregate amount of option shares shall vest on each of February 18, 2022, 2023 and 2024, respectively.
  4. One third of the aggregate amount of stock appreciation rights shall vest on each of February 18, 2022, 2023 and 2024, respectively.